Researchers found that Alumis’ experimental drug, envudeucitinib, did not meet its goals in a recent phase 2b trial for treating lupus, a chronic autoimmune disease. The trial involved 408 adults with moderately to severely active systemic lupus erythematosus (SLE) and aimed to assess the drug's effectiveness over 48 weeks. Although the drug failed to show significant benefits compared to a placebo, Alumis is moving forward with plans for a phase 3 trial based on promising results in a specific subgroup of patients who exhibited a high interferon gene signature.

This finding is particularly relevant for people living with lupus, a condition that can severely impact quality of life. The subgroup of patients with a high interferon gene signature showed a 52.6% response rate to the highest dose of envudeucitinib, compared to only 24.4% in those with a lower signature. This suggests that while the overall trial did not succeed, there may still be hope for a subset of patients who could benefit significantly from this treatment.

The evidence from the phase 2b trial is mixed. While the primary and secondary endpoints were not met, the data indicates that envudeucitinib may be effective for certain patients. Alumis plans to refine its approach by focusing on patients with the high interferon gene signature in the next trial. This strategy could provide more targeted treatment options for those with severe lupus symptoms. Additionally, Alumis is also preparing to seek approval for envudeucitinib in treating psoriasis, further indicating the drug's potential in autoimmune diseases.